Cancer pain

Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Forecasts, 2030 - Market Penetration, Developments, and Diversification; Marketed & Emerging Drugs, and Competitive Landscape Assessment - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Tetrodotoxin, USD, Chronic pain, CIPN, CK, Diagnosis, Cancer, Investment, Global, Adoption, Pfizer, Hoffmann-La Roche, Prevalence, Hyco International Inc, Research report, SWOT, Risk, Cancer pain, Population, CK Life Sciences, COVID-19, TTX, Growth, R, Awareness, Market development, Video game, Fine chemical, Pharmaceutical industry, Retail, Carbon fibers

Based on region, the Global Chemotherapy-Induced Peripheral Neuropathy market is divided into Europe, North America, Asia-Pacific, Middle East & Africa, and South America.

Key Points: 
  • Based on region, the Global Chemotherapy-Induced Peripheral Neuropathy market is divided into Europe, North America, Asia-Pacific, Middle East & Africa, and South America.
  • Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Global Chemotherapy-Induced Peripheral Neuropathy market have been provided in this research report.
  • The report answers questions such as:
    What is the market size and forecast of the Global Chemotherapy-Induced Peripheral Neuropathy Market?
  • What is the market share of the leading players in the Global Chemotherapy-Induced Peripheral Neuropathy Market?

Global Cancer Pain Market to 2030 - by Drug Type, Disease Indication, Estimation & Forecast - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Pharmaceutical, Health, Oncology, Tetra, Diagnosis, Patient, Investment, GDP, Prevalence, Government, Estimation, Drug, USD, SWOT, Awareness, Cancer pain, Cancer, Disease, National Cancer Institute, Pain, ESMO, Competitive landscape, OECD, R, Research report, Morphine, National, Dietary supplement

The "Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global cancer pain market accounted for a market size of USD 6,716.2 Million in 2021 and is projected to reach USD 9,951.2 Million by 2030, at a growth rate of 4.6% during the forecast period.
  • The global cancer pain market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide.
  • The global Cancer pain market report provides insights on the below pointers:
    Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
    Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global cancer pain market have been provided in this research report.

Oklahoma Cannabis Brand Chef Joey's Premium Edibles Announces Partnership with Children's Hospital Foundation for "Kisses for Cancer" Fundraising Initiative

Retrieved on: 
Friday, January 28, 2022
Awareness, Family, Cancer pain, Patient, Face, LLC, Timeline of cannabis laws in the United States, National Cancer Center, Research, Instagram, Partnership, Cannabinoid, Hospital, Health, BC Children's Hospital Foundation, Education, CHF, Medicine, Toy, Cancer

"Children's Hospital Foundation is grateful to partner with the JDMG Family to raise funds for pediatric cancer during the month of February," said Kathy McCracken, Executive Director of Children's Hospital Foundation.

Key Points: 
  • "Children's Hospital Foundation is grateful to partner with the JDMG Family to raise funds for pediatric cancer during the month of February," said Kathy McCracken, Executive Director of Children's Hospital Foundation.
  • Chief Executive Officer of JDMG, LLC, Dallas Owens, said "We are honored to be able to play a role in assisting Children's Hospital Foundation.
  • About JDMG, LLC: JDMG, LLC and the Delta Oil Co. family of brands including Chef Joey's Premium Edibles, Delta Oil Co. and Body Guac were established in Tulsa, Oklahoma in 2020.
  • To learn more about Children's Hospital Foundation visit, Oklahoma Children's Hospital Foundation ( chfkids.com ).

Global Cancer Pain Market (2021 to 2030) - by Drug Type and Disease Indication - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022
Pharmaceutical, Health, Oncology, COVID-19, Colorectal cancer, Therapy, Nonsteroidal anti-inflammatory drug, Awareness, Lymphatic system, Skin, Patient, Cancer pain, Hospital, Morphine, Pain, Paracetamol, Fentanyl, Cancer, Growth, Breast cancer, Adoption, Incidence, Lung cancer, Chronic pain, Neoplasm, Radiation, Prostate cancer, CAGR, Disease, Dietary supplement

The "Cancer Pain Market by Drug Type and Disease Indication: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Pain Market by Drug Type and Disease Indication: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • There is surge in the demand for cancer pain drugs owing to the growth in incidence of different forms of cancer, higher number of R&D studies to develop cancer pain therapeutics, and increase in adoption of cancer pain drugs.
  • According to the disease indication, the market is categorized into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the cancer pain market.

Cancer Pain Pipeline Guide for Drugs in Development 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 15, 2021
Pharmaceutical, Health, Oncology, Discovery, Mall of America, Central nervous system, Research, R, ROA, Therapy, History, News, Company, Decision-making, SEC, Dietary supplement, Pharmaceutical industry, Cancer pain

The "Cancer Pain (Central Nervous System) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Pain (Central Nervous System) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™

Retrieved on: 
Monday, November 29, 2021
Tetra, Patient, Somnolence, News, Insurance, CEO, Safety, Time, Forward-looking statement, Company, Sleep, Drug, Toxicity, Plasma, Confusion, THC, Cancer, Cancer pain, Pain management, Inflammation, Human, CBD, TSX, FRA, Pain, Legislation, Physician, Death, View, Risk, CRO, Research, Hypoventilation, Terminology, Plasma protein binding, Constipation, FDA, Journal, Multimedia, The Journal of Clinical Pharmacology, CGMP, TBP, Quality of life, Pharmaceutical industry

The PLENITUDE trial is a randomized double-blind phase 2 study assessing the safety and efficacy of QIXLEEF in patients with cancer who have uncontrolled pain.

Key Points: 
  • The PLENITUDE trial is a randomized double-blind phase 2 study assessing the safety and efficacy of QIXLEEF in patients with cancer who have uncontrolled pain.
  • Both studies are conducted across multiple clinical sites located in the United States.
  • Preliminary analysis of the data shows a positive effect on pain relief in QIXLEEFTM-treated patients.
  • Preliminary data from both REBORN1 and PLENITUDEconfirm the safety and pharmacodynamic profile of QIXLEEFreported in the phase I trials.

Global Pain Therapeutics Markets, Drugs, and Competitive Landscape Report 2021-2030 with Focus on Cancer, Arthritis, Postsurgical, Backache, Headache, Neuropathic, & Fibromyalgia - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 23, 2021
Pharmaceutical, Health, Clinical Trials, Well, Anesthetic, Patient, Table, Peptide, Sumatriptan, Substance P, Analgesic, Cancer pain, Ketamine, Pharmacogenomics, Acupuncture, Pain, Epidemiology, Tetrodotoxin, Neuropathic pain, Arthritis, N, Literature, Conotoxin, Migraine, Cannabinoid, Scale (music), Dentistry, Pharmaceutical industry

This report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.

Key Points: 
  • This report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.
  • Major segments of the pain market are arthritis, neuropathic pain and cancer pain.
  • Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal anti-inflammatory drugs such as COX-2 inhibitors.
  • Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery.

The Worldwide Pain Management Devices Industry is Expected to Reach $3.3 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 19, 2021
Medical Devices, Health, Patient, Asia, Ageing, Adoption, Pain, Peripheral neuropathy, Brain, Population, CAGR, Pain management, USD, Pump, Cancer pain, Lists of diseases, Ablation, MSK, Nature, SCS, Spinal cord, Chronic pain, NA, Quality of life, Neuropathic pain, Incidence, OTC, Region, Pain scale, TENS, Growth, Medical device, Dentistry

Based on type, the pain management devices market is segmented into neurostimulation devices, infusion pumps, and ablation devices.

Key Points: 
  • Based on type, the pain management devices market is segmented into neurostimulation devices, infusion pumps, and ablation devices.
  • Based on application, the pain management devices market is segmented into neuropathic pain, musculoskeletal pain, cancer pain, facial pain & migraine, and other applications.
  • The presence of substantial clinical evidences in the favor of high efficacy of pain management devices in neuropathic pain treatment, development of novel neuropathic pain management devices, rising aging population across the globe (geriatric population is at high risk of neuropathic pain due to the increased incidence of neuropathic pain associated with many age-related diseases), side effects of drugs used to treat neuropathic pain, and availability of reimbursement are fueling the adoption of pain management devices for neuropathic pain treatment are the major factors contributing to the growth of the pain management devices market for neuropathic pain applications.
  • The pain management devices market in the US is expected to offer growth opportunities in the coming years owing to the increasing adoption of pain management devices in ambulatory care centers.

Dr. Debashish Bose and The Institute for Cancer Care at Mercy to Participate in Study of Nanoknife for Late Stage Pancreatic Cancer

Retrieved on: 
Thursday, November 18, 2021
Patient, Membrane, Pancreatic cancer, Safety, Mercy Hospital, Pancreas, Nanoknife, Blood, Publication, 4th floor, Hospital, Surgical oncology, IRE, Associate Director of National Intelligence and Chief Information Officer, Cancer, Needle, Observational study, Cancer pain, Clinical trial, Institute, Institute of Liver and Biliary Sciences, Pain, Mercy, Physician, Center, Survival, Twitter, Research, Neoplasm, St Paul's Place, Electricity, Mortality, CT, Moyamoya disease, Disease, Facebook, Pharmaceutical industry, Medical imaging

Stage 3 means that the cancer has spread outside the pancreas, such as to the blood vessels near the pancreas.

Key Points: 
  • Stage 3 means that the cancer has spread outside the pancreas, such as to the blood vessels near the pancreas.
  • AngioDynamics is a global provider of industry-leading medical devices used worldwide for the treatment of cancer and peripheral vascular disease.
  • "The NanoKnife serves to permanently damage cancer cells that may be difficult to reach and treat with traditional methods.
  • Dr. Bose has been utilizing NanoKnife for treating later stage pancreatic cancer for more than 5 years with positive results.

DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM)

Retrieved on: 
Thursday, October 14, 2021
Tetra, Aerosol, Terminology, Cancer pain, QT, CNW, Inhalation, Liver, TBP, Drug discovery, Cancer, Risk, MAA, Cannabinoid, Pain, Physician, Adult, Marketing, CGMP, Population, Insurance, CBD, Brain, THC, CRO, FDA, Smoking, TSX, Legislation, Inflammation, Patient, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Science, Health Canada, Forward-looking statement, Company, FRA, Pain management, Drug development, CEO, Mycotoxin, Safety, Research, Plasma protein binding, Pharmacokinetics, Pharmaceutical industry, Medical device, Generic drug

Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • Having a global drug development strategy ensures economy of scale and lower cost of drug development to shareholders.
  • The REBORN(c) clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF(TM) to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF(TM) to a late clinical development stage.